Cargando…

Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition

Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few...

Descripción completa

Detalles Bibliográficos
Autores principales: Giurisato, Emanuele, Xu, Qiuping, Lonardi, Silvia, Telfer, Brian, Russo, Ilaria, Pearson, Adam, Finegan, Katherine G., Wang, Wenbin, Wang, Jinhua, Gray, Nathanael S., Vermi, William, Xia, Zhengui, Tournier, Cathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866536/
https://www.ncbi.nlm.nih.gov/pubmed/29507229
http://dx.doi.org/10.1073/pnas.1707929115
_version_ 1783308847364964352
author Giurisato, Emanuele
Xu, Qiuping
Lonardi, Silvia
Telfer, Brian
Russo, Ilaria
Pearson, Adam
Finegan, Katherine G.
Wang, Wenbin
Wang, Jinhua
Gray, Nathanael S.
Vermi, William
Xia, Zhengui
Tournier, Cathy
author_facet Giurisato, Emanuele
Xu, Qiuping
Lonardi, Silvia
Telfer, Brian
Russo, Ilaria
Pearson, Adam
Finegan, Katherine G.
Wang, Wenbin
Wang, Jinhua
Gray, Nathanael S.
Vermi, William
Xia, Zhengui
Tournier, Cathy
author_sort Giurisato, Emanuele
collection PubMed
description Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression.
format Online
Article
Text
id pubmed-5866536
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher National Academy of Sciences
record_format MEDLINE/PubMed
spelling pubmed-58665362018-03-29 Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition Giurisato, Emanuele Xu, Qiuping Lonardi, Silvia Telfer, Brian Russo, Ilaria Pearson, Adam Finegan, Katherine G. Wang, Wenbin Wang, Jinhua Gray, Nathanael S. Vermi, William Xia, Zhengui Tournier, Cathy Proc Natl Acad Sci U S A PNAS Plus Owing to the prevalence of tumor-associated macrophages (TAMs) in cancer and their unique influence upon disease progression and malignancy, macrophage-targeted interventions have attracted notable attention in cancer immunotherapy. However, tractable targets to reduce TAM activities remain very few and far between because the signaling mechanisms underpinning protumor macrophage phenotypes are largely unknown. Here, we have investigated the role of the extracellular-regulated protein kinase 5 (ERK5) as a determinant of macrophage polarity. We report that the growth of carcinoma grafts was halted in myeloid ERK5-deficient mice. Coincidentally, targeting ERK5 in macrophages induced a transcriptional switch in favor of proinflammatory mediators. Further molecular analyses demonstrated that activation of the signal transducer and activator of transcription 3 (STAT3) via Tyr705 phosphorylation was impaired in erk5-deleted TAMs. Our study thus suggests that blocking ERK5 constitutes a treatment strategy to reprogram macrophages toward an antitumor state by inhibiting STAT3-induced gene expression. National Academy of Sciences 2018-03-20 2018-03-05 /pmc/articles/PMC5866536/ /pubmed/29507229 http://dx.doi.org/10.1073/pnas.1707929115 Text en Copyright © 2018 the Author(s). Published by PNAS. https://creativecommons.org/licenses/by-nc-nd/4.0/ This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle PNAS Plus
Giurisato, Emanuele
Xu, Qiuping
Lonardi, Silvia
Telfer, Brian
Russo, Ilaria
Pearson, Adam
Finegan, Katherine G.
Wang, Wenbin
Wang, Jinhua
Gray, Nathanael S.
Vermi, William
Xia, Zhengui
Tournier, Cathy
Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title_full Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title_fullStr Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title_full_unstemmed Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title_short Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition
title_sort myeloid erk5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via stat3 inhibition
topic PNAS Plus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866536/
https://www.ncbi.nlm.nih.gov/pubmed/29507229
http://dx.doi.org/10.1073/pnas.1707929115
work_keys_str_mv AT giurisatoemanuele myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT xuqiuping myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT lonardisilvia myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT telferbrian myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT russoilaria myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT pearsonadam myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT finegankatherineg myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT wangwenbin myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT wangjinhua myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT graynathanaels myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT vermiwilliam myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT xiazhengui myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition
AT tourniercathy myeloiderk5deficiencysuppressestumorgrowthbyblockingprotumormacrophagepolarizationviastat3inhibition